This Article Figures Only Full Text Full Text (PDF) View Related Journal Scan on Cardiosource Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Patti, G. Articles by Di Sciascio, G. Search for Related Content PubMed Articles by Patti, G. Articles by Di Sciascio, G. Related Collections Related Article

CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY

Point-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention

Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) Study

Department of Cardiovascular Sciences, Campus Bio-Medico University of Rome, Rome, Italy

Manuscript received March 25, 2008; revised manuscript received June 5, 2008, accepted June 9, 2008.

^_* Reprint requests and correspondence: Prof. Germano Di Sciascio, Department of Cardiovascular Sciences, Campus Bio-Medico University, Via Alvaro del Portillo, 200, 00128 Rome, Italy (Email: g.disciascio{at}unicampus.it).

Objectives: The aim of this study was to evaluate the correlation of point-of-care measurement of platelet inhibition with clinical outcome in patients undergoing percutaneous coronary intervention (PCI).

Background: Individual variability of clopidogrel response might influence results of PCI.

Methods: A total of 160 patients receiving clopidogrel before PCI were prospectively enrolled. Platelet reactivity was measured by the VerifyNow P2Y12 assay (Accumetrics Inc., San Diego, California). Primary end point was 30-day occurrence of major adverse cardiac events (MACE) according to quartile distribution of P2Y12 reaction units (PRU).

Results: Primary end point occurred more frequently in patients with pre-procedural PRU levels in the fourth quartile versus those in the lowest quartile (20% vs. 3%; p = 0.034), and it was entirely due to periprocedural myocardial infarction (MI). Mean PRU absolute levels were higher in patients with periprocedural MI (258 ± 53 vs. 219 ± 69 in patients without; p = 0.030). On multivariable analysis pre-PCI PRU levels in the fourth quartile were associated with 6-fold increased risk of 30-day MACE (odds ratio: 6.1; 95% confidence interval: 1.1 to 18.3, p = 0.033). By receiver-operating characteristic curve analysis, the optimal cut-off for the primary end point was a pre-PCI PRU value 240 (area under the curve: 0.69; 95% confidence interval: 0.56 to 0.81, p = 0.016).

Conclusions: This study indicates that high pre-PCI platelet reactivity might predict 30-day events. Use of a rapid point-of-care assay for monitoring residual platelet reactivity after clopidogrel administration might help identify patients in whom individualized antiplatelet strategies might be indicated with coronary intervention.

Key Words: clopidogrel • percutaneous coronary intervention • platelet aggregometry

Abbreviations and Acronyms   ACS = acute coronary syndromes   ADP = adenosine diphosphate   CK-MB = creatine kinase-myocardial band   LTA = light transmittance aggregometry   MACE = major adverse cardiac events   MI = myocardial infarction   PCI = percutaneous coronary intervention   PRU = platelet (P2Y12) reaction units   ROC = receiver-operating characteristic   Tn = troponin

Related Article

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 52: A31-A32. [Full Text] [PDF]

This article has been cited by other articles:

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097. [Full Text] [PDF]

				M. J. Price Bedside Evaluation of Thienopyridine Antiplatelet Therapy Circulation, May 19, 2009; 119(19): 2625 - 2632. [Full Text] [PDF]

				D. L. BHATT, K. KOTTKE-MARCHANT, J. H. ALEXANDER, W. F. PEACOCK, and M. S. SABATINE Platelet response in practice: Applying new insights and tools for testing and treatment Cleveland Clinic Journal of Medicine, April 1, 2009; 76(Suppl_1): S24 - S32. [Full Text] [PDF]

				D. Sibbing, S. Braun, T. Morath, J. Mehilli, W. Vogt, A. Schomig, A. Kastrati, and N. von Beckerath Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J. Am. Coll. Cardiol., March 10, 2009; 53(10): 849 - 856. [Abstract] [Full Text] [PDF]

				A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al. Highlights of the Year in JACC 2008. J. Am. Coll. Cardiol., January 27, 2009; 53(4): 373 - 398. [Full Text] [PDF]

				R. Marcucci, A. M. Gori, R. Paniccia, B. Giusti, S. Valente, C. Giglioli, P. Buonamici, D. Antoniucci, R. Abbate, and G. F. Gensini Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay: A 12-Month Follow-Up Circulation, January 20, 2009; 119(2): 237 - 242. [Abstract] [Full Text] [PDF]